Arpit Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
- Paid Up Capital ₹ 2.90 M
- Company Age 27 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.70 Cr
- Revenue Growth -20.05%
- Profit Growth -28.62%
- Ebitda -83.88%
- Net Worth 9.02%
- Total Assets 9.27%
About Arpit Pharmaceuticals
Arpit Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 April 1997 and has a history of 27 years and ten months. Its registered office is in Delhi, India.
The Company is engaged in the Transport And Logistics Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 2.90 M.
The company has closed loans amounting to ₹1.70 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Arvind Kumar and Anita Kumari serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232DL1997PTC086333
-
Company No.
086333
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 Apr 1997
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Arpit Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arvind Kumar
|
Director | 01-Apr-1997 | Current |
|
Anita Kumari
|
Director | 01-Apr-1997 | Current |
Financial Performance of Arpit Pharmaceuticals.
Arpit Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 20.05% decrease. The company also saw a substantial fall in profitability, with a 28.62% decrease in profit. The company's net worth moved up by a moderate rise of 9.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arpit Pharmaceuticals?
In 2023, Arpit Pharmaceuticals had a promoter holding of 21.86% and a public holding of 78.14%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Celsius Healthcare Private LimitedArvind Kumar is a mutual person
Charges (Loans)
₹0
₹16.97 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 1.40 Cr
- Citibank N.A. : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jul 2021 | Hdfc Bank Limited | ₹1.44 M | Satisfied |
| 23 Jun 2007 | Hdfc Bank Limited | ₹1.25 Cr | Satisfied |
| 30 Mar 2006 | Citibank N.A. | ₹3.00 M | Satisfied |
How Many Employees Work at Arpit Pharmaceuticals?
Unlock and access historical data on people associated with Arpit Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arpit Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arpit Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.